GI Oncology Now Conference Coverage
GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.
Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
Advertisement
The Latest From GI Oncology Now
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.